Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Myeloproliferative Disorders 5Myelodysplastic Syndromes 5Leukemia 5Myelodysplastic-Myeloproliferative Diseases 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Primary Myelofibrosis 2Leukemia, Myelomonocytic, Chronic 2Anemia, Refractory, with Excess of Blasts 2Thrombocythemia, Essential 1Precancerous Conditions 1Polycythemia Vera 1Multiple Myeloma 1Mastocytosis, Systemic 1Leukemia, Promyelocytic, Acute 1Leukemia, Myeloid, Acute 1Hematologic Diseases 1Graft vs Host Disease 1Congenital Abnormalities 1Blast Crisis 1Anemia, Refractory 1Anemia 1

Interventions

fludarabine phosphate 25Cyclophosphamide 24Peripheral Blood Stem Cell Transplantation 23Busulfan 17Tacrolimus 15Methotrexate 13Cyclosporine 13ruxolitinib 12Whole-Body Irradiation 12Mycophenolic Acid 12Antilymphocyte Serum 11Filgrastim 8Decitabine 7fludarabine 6Etoposide 611-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 6peginterferon alfa-2a 5Radiotherapy 5Methylprednisolone 5Cytarabine 5Carboplatin 5Prednisone 4Melphalan 4Flow Cytometry 4Biopsy 4Aspirin 4givinostat hydrochloride 3givinostat 3bomedemstat 3anagrelide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thrombocythemia, Essential × Thalidomide × Myeloid × Clear all
NCT00445900 2011-03-17

Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia

Mayo Clinic

Phase 2 Completed
22 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡